/NLTX
NLTX Stock - Neoleukin Therapeutics, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$3.49+1.45%
+$0.05 (+1.45%) • Dec 18
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.84
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NLTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.46 – $3.52
TARGET (TP)$4.01
STOP LOSS$3.21
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.10
52W High$18.80
52W Low$3.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $6,000 | $451,000 | N/A |
| Gross Profit | N/A | N/A | $6,000 | $451,000 | N/A |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | N/A |
| Operating Income | $-82,605,000 | $-59,097,000 | $-60,698,000 | $-33,728,000 | $-70,959,000 |
| Net Income | $-75,144,000 | $-57,557,000 | $-60,692,000 | $-33,277,000 | $-69,442,000 |
| Net Margin | N/A | N/A | -1011533.3% | -7378.5% | N/A |
| EPS | $-3.96 | $-5.07 | $-5.31 | $-3.20 | $-12.85 |
Company Overview
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NLTXBeat Rate
60%
Last 20 quarters
Avg Surprise
-64.4%
EPS vs Estimate
Beats / Misses
12/6
2 met exactly
Latest EPS
$-0.41
Q4 2023
EPS Surprise History
Q1 22
+6.7%
$-1.40vs$-1.50
Q2 22
+6.7%
$-1.40vs$-1.50
Q3 22
+6.7%
$-1.40vs$-1.50
Q4 22
+25.0%
$-1.20vs$-1.60
Q1 23
-731.6%
$-1.20vs$0.19
Q2 23
-11.1%
$-1.00vs$-0.90
Q3 23
+73.3%
$-0.20vs$-0.75
Q4 23
+48.8%
$-0.41vs$-0.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 14, 2023 | $-0.80 | $-0.41 | +48.8% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.75 | $-0.20 | +73.3% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.90 | $-1.00 | -11.1% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $0.19 | $-1.20 | -731.6% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.60 | $-1.20 | +25.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.50 | $-1.40 | +6.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-1.50 | $-1.40 | +6.7% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-1.50 | $-1.40 | +6.7% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-1.40 | $-1.40 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-1.35 | $-1.35 | 0.0% | = MET |
Q2 2021 | May 12, 2021 | $-1.20 | $-1.35 | -12.5% | ✗ MISS |
Q1 2021 | Mar 25, 2021 | $-1.05 | $-1.20 | -14.3% | ✗ MISS |
Q4 2020 | Nov 9, 2020 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q3 2020 | Aug 12, 2020 | $-0.95 | $-1.00 | -5.3% | ✗ MISS |
Q2 2020 | May 6, 2020 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q1 2020 | Mar 12, 2020 | $-2.70 | $-1.15 | +57.4% | ✓ BEAT |
Q4 2019 | Nov 13, 2019 | $-0.20 | $-2.20 | -1000.0% | ✗ MISS |
Q3 2019 | Aug 1, 2019 | $-0.05 | $-0.00 | +99.9% | ✓ BEAT |
Q2 2019 | May 7, 2019 | $-0.23 | $-0.09 | +60.9% | ✓ BEAT |
Q1 2019 | Mar 7, 2019 | $-0.79 | $-0.21 | +73.4% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about NLTX
What is NLTX's current stock price?
Neoleukin Therapeutics, Inc. (NLTX) is currently trading at $3.49 per share. The stock has moved +1.45% today.
What is the analyst price target for NLTX?
No analyst price targets are currently available for this stock.
What sector is Neoleukin Therapeutics, Inc. in?
Neoleukin Therapeutics, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is NLTX's market cap?
Neoleukin Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does NLTX pay dividends?
No, Neoleukin Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
CHRO
Channel Therapeutics Corporation
$1.35
Mkt Cap: $0.0B
CNTG
Centogene N.V.
$0.33
Mkt Cap: $0.0B
CSCI
COSCIENS Biopharma Inc.
$2.11
Mkt Cap: $0.0B
DMKPQ
DMK Pharmaceuticals Corporation
$0.00
Mkt Cap: $0.0B
LCI
Lannett Company, Inc.
$0.69
Mkt Cap: $0.0B
OMGA
Omega Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
OSA
ProSomnus, Inc.
$0.47
Mkt Cap: $0.0B
TSBX
Turnstone Biologics Corp.
$0.35
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to NLTX for comparison